Most People Who Stop GLP-1 Drugs End Up Back On Them, Conference Study Finds

What the Researchers Reported

At ENDO 2026, the Endocrine Society's annual meeting, researchers presented an analysis of treatment patterns among people taking GLP-1 receptor agonists — the drug class that includes liraglutide, semaglutide, and tirzepatide — for type 2 diabetes. Their central finding: stopping the medication and later restarting it is considerably more common than the standard "start and stay on it" picture suggests.

In other words, the real-world experience of taking a GLP-1 drug is less a straight line and more a series of starts, stops, and restarts. People come off these medications for a range of reasons — cost, side effects, supply gaps, insurance changes, or simply feeling they no longer need them — and a substantial share later return to treatment.

One Important Caveat First

This research was presented at a scientific conference. It has not yet completed peer review or been published in a final journal article. Conference presentations are an early stage in the scientific process: they share preliminary findings with the field, but the data, methods, and conclusions can still change before formal publication. Treat what follows as an early signal worth knowing about, not a settled result.

Why the Stop-and-Restart Pattern Matters

The reason this finding is interesting has less to do with the specific numbers and more to do with what it implies about the decision to start. A lot of public conversation about GLP-1 drugs frames the choice as binary and permanent: you go on them, and you stay on them indefinitely, because the weight tends to return when you stop.

The weight-regain pattern after stopping is well documented and not in dispute. But the conference data suggests the lived reality is messier. Many people are not making a single, once-and-for-all decision. They are cycling — pausing treatment and resuming it as circumstances shift. That is a meaningfully different mental model, and it changes what questions are worth asking before starting.

The "Off-Ramp" Conversation

If stopping and restarting is common, then the off-ramp deserves as much attention as the on-ramp. Before starting a GLP-1 medication, it is reasonable to ask: what happens if I need to stop? What does coming off look like — for appetite, for weight, for blood sugar? If I restart later, do I begin again at a low dose? These are questions a prescriber can answer, and the conference findings are a good reason to raise them up front rather than after the fact.

This matters in particular for people navigating weight management in midlife, where metabolism, hormones, and life circumstances are all in flux. The point is not that anyone should stop — or start — a medication based on a conference abstract. The point is that the path is rarely linear, and going in with that expectation makes the whole process easier to plan around.

What This Is, and Isn't

This is a report on an early-stage research finding about how people actually use GLP-1 medications. It is not medical advice, and it is not a recommendation to start, stop, or change any treatment. Decisions about GLP-1 drugs — which are prescription medications — belong with a qualified healthcare provider who knows your history. What the research adds is a more honest frame: for many people, GLP-1 treatment is something they move on and off of over time, not a one-way door.